Loading
A phase 2/3 trial testing ICP-248 in chronic lymphocytic leukaemia, now recruiting.
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (APEX-03) is a phase 2/3 interventional study registered as NCT06378138, led by Beijing InnoCare Pharma Tech, and recruiting on the registry. Official title: A Phase II/III Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma. Planned enrolment is 226 participants (estimated). The study started in 2024-05-15 and primary completion is expected in 2030-11-25. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ICP-248, InnoCare Pharma.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/